vimarsana.com
Home
Live Updates
IO-202 Receives FDA Orphan Drug Designation for CMML : vimar
IO-202 Receives FDA Orphan Drug Designation for CMML : vimar
IO-202 Receives FDA Orphan Drug Designation for CMML
The FDA has granted IO-202 an orphan drug designation for patients with chronic myelomonocytic leukemia.
Related Keywords
Germany ,
,
Onc Therapeutics Inc ,
European Hematology Association Congress ,
Liao Phd ,
Onc Therapeutics ,
Hematology Association Congress ,
Io 202 ,
Patients With Chronic Myelomonocytic Leukemia ,
Charlene Liao Phd ,
Nct04372433 ,